
LRMR Stock Forecast & Price Target
LRMR Analyst Ratings
Bulls say
Larimar Therapeutics is on track with its BLA submission for nomlabofusp in 2Q26 and expects to see a potential launch in 2Q27 for its treatment for Friedreich's ataxia. They have the potential to receive a PRV upon approval and are expected to seek external funding in the future. This, coupled with their promising intracellular delivery platform, make them a strong investment opportunity.
Bears say
Larimar Therapeutics is expected to face regulatory and data updates for their flagship drug, nomlabofusp, in the near-term, potentially serving as a primary driver for the stock, with a June 2026 BLA submission date and a potential priority review of 6 months. While the company currently has a strong cash runway through 2Q27, their lack of marketable products and potential delays in the BLA submission process may lead to continued negative financial performance.
This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LRMR Analyst Forecast & Price Prediction
Start investing in LRMR
Order type
Buy in
Order amount
Est. shares
0 shares